Patents by Inventor David Lubkowicz

David Lubkowicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF
    Publication number: 20260199405
    Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with amino acid metabolism, including homocystinuria, in a subject.
    Type: Application
    Filed: June 23, 2023
    Publication date: July 16, 2026
    Inventors: Aoife Brennan, Caroline Kurtz, Neal Sondheimer, Michael James, David Lubkowicz
  • Bacteria for the treatment of disorders
    Patent number: 12545886
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: February 10, 2026
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • BACTERIA FOR THE TREATMENT OF DISORDERS
    Publication number: 20240368531
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Application
    Filed: November 17, 2023
    Publication date: November 7, 2024
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20240316121
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 26, 2024
    Inventors: Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Koniecza, Catherine Monahan, Vincent M. Isabella, David Lubkowicz
  • BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL
    Publication number: 20240197843
    Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
    Type: Application
    Filed: March 24, 2022
    Publication date: June 20, 2024
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Vincent M. Isabella, David Lubkowicz, Michael James, Caroline Kurtz
  • Bacteria for the treatment of disorders
    Patent number: 11879123
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 23, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL
    Publication number: 20230092431
    Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 23, 2023
    Inventors: Vincent M. Isabella, David Lubkowicz, Michael James
  • BACTERIA FOR THE TREATMENT OF DISORDERS
    Publication number: 20200172857
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Application
    Filed: June 21, 2018
    Publication date: June 4, 2020
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe